Lisa Blackwell
Senior Statistical Programmer
- Vascular Overviews Group/Renal Studies Group
Lisa is a Senior Statistical Programmer at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU).
She completed her degree in Applied Statistics at the University of Plymouth, and is now the statistical programming lead for the ATT (Anti-Thrombotic Trialists’ Collaboration), CTT (Cholesterol Treatment Trialists’ Collaboration) and STT (Stroke Thrombolysis Trialists’ Collaboration) projects within the CTSU’s Vascular Overviews Group.
Her research interests focus on cardiovascular disease, large-scale individual participant meta-analyses of randomised studies and methods for harmonisation of large-scale heterogeneous IPDs.
She is a member of the board of examiners for the Oxford Population Health MSc in Clinical Trials and an assessor for MSc in Global Health Science.
Recent publications
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
-
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
-
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
Journal article
BAIGENT C. et al, (2022), The Lancet
-
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials
-
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415
-
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
Journal article
3C Study Collaborative Group None., (2018), Am J Transplant, 18, 1424 - 1434
-
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.
Journal article
Hacke W. et al, (2018), Int J Stroke, 13, 175 - 189
-
Interpretation of the evidence for the efficacy and safety of statin therapy.
Journal article
Collins R. et al, (2016), Lancet, 388, 2532 - 2561
-
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2016), Lancet Diabetes Endocrinol, 4, 829 - 839
-
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.
Journal article
Lees KR. et al, (2016), Stroke, 47, 2373 - 2379